Immune Therapeutics, Inc. (IMUN) financial statements (2022 and earlier)

Company profile

Business Address 2431 ALOMA AVE #124
WINTER PARK, FL 32792
State of Incorp. FL
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,1392,6862312103145
Cash and cash equivalents494292312103145
Short-term investments2,6452,657     
Total current assets:3,1392,6862312103145
Noncurrent Assets
Property, plant and equipment     00
Other undisclosed noncurrent assets   0000
Total noncurrent assets:   0001
TOTAL ASSETS:3,1392,6862312103146
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,4106,3186,9547,0607,0467,3227,771
Accounts payable2,1852,1832,5842,7112,5632,8132,777
Accrued liabilities2402402812682213,9344,994
Employee-related liabilities3,4213,3773,6033,6283,628  
Interest and dividends payable564518486454635575 
Debt3,0703,0703,0703,0702,8452,8925,580
Derivative instruments and hedges, liabilities    1,2549621,903
Due to related parties8918017166265314676
Other undisclosed current liabilities716240140    
Total current liabilities:11,08710,43010,88010,75611,67711,22215,331
Noncurrent Liabilities
Total liabilities:11,08710,43010,88010,75611,67711,22215,331
Stockholders' equity
Stockholders' equity attributable to parent, including:(7,948)(7,744)(10,857)(10,744)(11,667)(11,191)(15,285)
Common stock0000000
Additional paid in capital371,474371,474371,474371,474371,341370,908370,908
Accumulated deficit(379,432)(379,228)(382,341)(382,228)(383,018)(382,109)(386,203)
Other undisclosed stockholders' equity attributable to parent10101010101010
Total stockholders' equity:(7,948)(7,744)(10,857)(10,744)(11,667)(11,191)(15,285)
TOTAL LIABILITIES AND EQUITY:3,1392,6862312103146

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Operating expenses(147)(115)(189)287(343)(131)(18)
Other undisclosed operating loss   (575)   
Operating loss:(147)(115)(189)(287)(343)(131)(18)
Nonoperating income (expense)(58)3,228771,078(567)4,225(786)
Investment income, nonoperating(12)3,260     
Interest and debt expense(0)603(32)(100)4843,232(127)
Income (loss) before gain (loss) on sale of properties:(205)3,716(145)690(426)7,326(931)
Other undisclosed net income (loss)    3,018(3,232)127
Net income (loss):(205)3,716(145)6902,5934,094(804)
Other undisclosed net income (loss) attributable to parent0(603)32100(3,502)  
Net income (loss) available to common stockholders, basic:(205)3,113(113)790(909)4,094(804)
Dilutive securities, effect on basic earnings per share    33  
Net income (loss) available to common stockholders, diluted:(205)3,113(113)790(877)4,094(804)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net income (loss):(205)3,716(145)6902,5934,094(804)
Comprehensive income (loss), net of tax, attributable to parent:(205)3,716(145)6902,5934,094(804)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: